Idecabtagene vicleucel (Intravenous)
Medically reviewed by Drugs.com. Last updated on Dec 31, 2021.
Warning: Cytokine Release Syndrome, Neurologic Toxicities, HLH/MAS, and Prolonged CytopeniaCytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with idecabtagene vicleucel. Do not administer idecabtagene vicleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.Neurologic toxicities, which may be severe or life-threatening, occurred following treatment with idecabtagene vicleucel, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with idecabtagene vicleucel. Provide supportive care and/or corticosteroids as needed.Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with idecabtagene vicleucel. HLH/MAS can occur with CRS or neurologic toxicities.Prolonged cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with idecabtagene vicleucel.Idecabtagene vicleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS .
Commonly used brand name(s)
In the U.S.
- Abecma
Available Dosage Forms:
- Suspension
Therapeutic Class: Antineoplastic Agent
Chemical Class: CAR T-Cell Agent
Uses for idecabtagene vicleucel
Idecabtagene vicleucel injection is used treat multiple myeloma (bone marrow cancer) in patients whose cancer has come back and who have received at least 4 previous treatments (eg, an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well.
Idecabtagene vicleucel injection is an antineoplastic (cancer) medicine that is made from your own white blood cells, which have been modified to recognize and attack your cancer cells. Before you begin treatment, talk to your doctor about the benefits of idecabtagene vicleucel as well as the possible risks of receiving it.
Idecabtagene vicleucel is available only under a restricted distribution program called Abecma® REMS (Risk Evaluation and Mitigation Strategy) Program.
Before using idecabtagene vicleucel
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For idecabtagene vicleucel, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to idecabtagene vicleucel or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of idecabtagene vicleucel injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have n..
